News Center

News Center

Home page

Blog Center

News Center

Viwit Pharmaceuticals' Sterile Production Facility Successfully Passes U.S. FDA Inspection

Viwit Pharmaceutical's Phenylephrine Hydrochloride Injection Officially Receives Official Approval by China NMPA

Viwit Pharmaceuticals’ Brimonidine tartrate and Timolol maleate eye drops receive Official Approval by China NMPA

Viwit's Nitroglycerin Sublingual Tablets Approved by FDA

Viwit Pharmaceuticals API Site Successfully Passed FDA cGMP On-site Audit with "No Action Indicated"

Viwit Pharmaceutical Co. Ltd. announces exclusive licensing and supply agreement for two Gadolinium based Magnetic Resonance Imaging (MRI) injectable contrast agents in the US.

Welcome participants in CPhI China 2018, booth: W2A09

Author：

Release Time：

2018-06-20

CPhI China 2018 will be held at Shanghai New International Expo Center from June 20th to 22nd, 2018. Welcome to patronize Viwit, booth number: W2A09. If you would like to make an appointment in advance, please email us at service@viwit.com.

Previous

Welcome participants in CPhI Worldwide 2018, booth number: 7A80

Next

VIWIT

Technical Support:China Enterprise Cross-border | SEO Tags

【Business License】

Search